Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-02T16:22:30.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    A sitewide NIH notice appears above the page, linking to transition updates and stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T15:45:41.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2 on the page displaying a 403 error.
    Difference
    0.2%
    Check dated 2026-10-19T17:18:20.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T18:07:24.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden message with a Home link in place of its record content.
    Difference
    0.5%
    Check dated 2026-10-05T19:57:18.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record details. Access to the study content is blocked.
    Difference
    17%
    Check dated 2026-09-21T22:42:06.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.